Telemedicine for Individuals with epilepsy: Recommendations from the International League Against Epilepsy Telemedicine Task Force
- PMID: 36803864
- DOI: 10.1016/j.seizure.2023.02.005
Telemedicine for Individuals with epilepsy: Recommendations from the International League Against Epilepsy Telemedicine Task Force
Abstract
Worldwide, People with Epilepsy (PWE) are confronted with several barriers to face-to-face consultations. These obstacles hamper appropriate clinical follow-up and also increase the treatment gap for Epilepsy. Telemedicine holds the potential to enhance management as follow-up visits for PWE are focused on more on clinical history and counselling rather than physical examination. Besides consultation, telemedicine can also be used for remote EEG diagnostics and tele-neuropsychology assessments. In this article, the Telemedicine Task Force of the International League Against Epilepsy (ILAE) outlines recommendations regarding optimal practice in utilizing in the management of individuals with epilepsy. We formulated recommendations for minimum technical requirements, preparing for the first tele-consultation and the specificities for follow-up consultations. Special considerations are necessary for specific populations, including paediatric patients, patients who are not conversant with tele-medicine and those with intellectual disability. Telemedicine for individuals with epilepsy should be vigorously promoted with the aim of improving the quality of care and ultimately reduce the wide clinician access related treatment gap across several regions of the globe.
Keywords: Epilepsy; Telemedicine; Teleneurology; Treatment gap.
Copyright © 2023. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest Samia P: none, Caraballo R:none, Coan AC: none; Zelano J: none; Sarfo FS: none; Eugen Trinka received honoraria from EVER Pharma, Marinus, Arvelle, Angelini, Argenx, Marinus, Medtronic, Bial-Portela & Cª, NewBridge, GL Pharma, GlaxoSmithKline, Boehringer Ingelheim, LivaNova, Eisai, UCB, Biogen, Genzyme Sanofi, GW/Jazz Pharmaceuticals, and Actavis. His-institution received grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF Österreichischer Fond zur Wissenschaftsforderung, Bundesministerium für Wissenschaft und Forschung, and Jubiläumsfond der Österreichischen Nationalbank. Jitendra Sahu has received honorarium from the Indian Journal of Pediatrics for working as a Section Editor. He also received research grant support paid to his institution from the Indian Council of Medical Research, New Delhi. J Helen Cross has acted as an investigator for studies with GW Pharma, Ovid Therapeutics, Zogenix, Vitaflo, Marinius and Stoke Therapeutics. She has been a speaker and on advisory boards for GW Pharma, Zogenix, UCB and Nutricia; all remuneration has been paid to her department. She holds an endowed chair at UCL Great Ormond Street Institute of Child Health; she holds grants from NIHR, EPSRC, GOSH Charity, ERUK, the Waterloo Foundation and the National Institute of Health Research (NIHR) Biomedical Research Centre at Great Ormond Street Hospital.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
